Nichole Tucker

Articles

Investigators Debate Frontline Doublet Vs Triplet Therapy in RCC

November 5th 2022

Rana M. McKay, MD, and Yousef Zakharia, MD, debate the pros and cons of doublet vs triplet combination therapies in the frontline setting for patients with renal cell carcinoma.

Checkpoint Inhibition Prevails as Frontline Standard in BRAF-Mutant Melanoma

October 11th 2022

Findings from the DREAMseq trial indicate that nivolumab plus ipilimumab should be administered prior to the combination of a BRAF and MEK inhibitor in patients with advanced BRAF-mutant melanoma.

Belantamab Mafodotin Combination Elicits Encouraging ORRs in Relapsed/Refractory Multiple Myeloma

October 1st 2022

Belantamab mafodotin plus lenalidomide and dexamethasone showed durable responses in patients with relapsed/refractory multiple myeloma.

Ivosidenib/Azacitidine Combo Elicits Survival Benefit Over Placebo in IDH1-Mutated AML

September 29th 2022

Ivosidenib plus azacitidine displayed favorable event-free survival, overall survival, and clinical responses compared with placebo plus azacitidine in patients with newly diagnosed, IDH1-mutated acute myeloid leukemia, according to findings from the phase 3 AGILE study.

Busulfan/Melphalan Prior to ASCT Fails to Elicit PFS Benefit in Newly Diagnosed Myeloma

August 28th 2022

High-dose busulfan plus melphalan failed to generate a progression-free survival benefit vs melphalan for autologous stem cell transplant conditioning in patients with newly diagnosed multiple myeloma after induction therapy.

Larotrectinib Delivers Durable Improvement in HRQoL in TRK Fusion Cancers

June 7th 2022

Treatment with larotrectinib led to early onset and clinically meaningful improvements in health-related quality of life that were sustained for more than 12 months in most adult and pediatric patients with TRK fusion lung cancer, according to results from an expanded dataset.

Significant Enrichment of CDKN2A/B Alterations Found in Patients With NSCLC and Brain Mets

June 7th 2022

Significant enrichment of CDKN2A/B and cell cycle pathway alterations were observed in patients with non–small cell lung cancer and brain metastases vs extracranial disease, and a higher fraction of the genome was altered in these patients vs matched primary tumor controls.

Larotrectinib Continues to Demonstrate High DCR, Elicit Durable Responses in TRK Fusion+ CNS Tumors

June 5th 2022

Larotrectinib continued to produce rapid and durable responses, with a high disease control rate and an acceptable toxicity profile in patients with TRK fusion–positive, primary central nervous system tumors.

Hyper-CVAD Plus Sequential Blinatumomab With or Without Inotuzumab Elicits Clinical Benefit in Ph-Negative B-Cell ALL

June 4th 2022

Sequential administration of blinatumomab with or without inotuzumab following hyper-CVAD elicited high rates of minimal residual disease negativity and a durable overall survival benefit among patients with Philadelphia chromosome-negative B-cell acute lymphoblastic lymphoma.

Darolutamide Maintains OS Benefit in Castration-Resistant Prostate Cancer

May 14th 2022

Darolutamide elicited consistent benefits in overall survival and prostate-specific antigen outcomes, irrespective of prior local therapy with radiotherapy or radical prostatectomy, in patients with nonmetastatic castration-resistant prostate cancer.

Frontline Axi-cel Elicits Rapid, Durable Responses in High-Risk Large B-Cell Lymphoma

April 24th 2022

The CAR T-cell therapy axicabtagene ciloleucel produced encouraging responses when used in the first-line treatment of patients with high-risk large B-cell lymphoma.

CoVac-1 Vaccination Could Prevent Severe COVID-19 in Patients with Cancer and Immunoglobulin Deficiency

April 12th 2022

CoVac-1, a multi-peptide COVID-19 vaccine, elicited promising T-cell activity and safety in patients with cancer who have disease- or treatment-related immunoglobulin deficiency.

Combined Immune Pathway Inhibition Improves Responses in Resectable NSCLC

April 11th 2022

Durvalumab plus either oleclumab, monalizumab, or damvatirsen led to an improvement in major pathologic response vs durvalumab alone as neoadjuvant therapy in patients with resectable, early-stage non–small cell lung cancer, according to findings from the phase 2 NeoCOAST clinical trial.

Abemaciclib/Endocrine Therapy Combo Showcases Long-Term Clinical Benefit in HR+ High-Risk Early Breast Cancer

March 5th 2022

The combination of adjuvant abemaciclib and endocrine therapy led to a clinically meaningful benefit at 3 years in patients with hormone receptor–positive, HER2-negative, node-positive, early breast cancer.

Immune Cell–Related Parameters May Serve as Biomarkers for Response to Nivolumab/Ipilimumab in Clear Cell RCC

February 19th 2022

Efficacy rates generated by the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) vary based on certain immune-cell related parameters in patients with advanced or metastatic clear cell renal cell carcinoma.

Onvansertib Plus FOLFIRI/Bevacizumab Generates Meaningful Responses in KRAS-Mutant mCRC

January 22nd 2022

Onvansertib in combination with irinotecan, fluorouracil, and folinic acid, plus bevacizumab, demonstrated encouraging efficacy and was well-tolerated in patients with KRAS-mutated metastatic colorectal cancer.

Lower Doses of Selinexor Plus Bortezomib and Dexamethasone Show Best Efficacy and Safety in Myeloma

December 14th 2021

Lower 60mg and 40mg doses of Selinexor in combination with bortezomib and dexamethasone demonstrated improved efficacy and safety vs a 100mg dose for patients with relapsed or refractory multiple myeloma.

Weekly Selinexor/Bortezomib/Dexamethasone Combo Demonstrates Favorable Efficacy and Safety in High-Risk Multiple Myeloma

December 12th 2021

Weekly selinexor plus bortezomib and dexamethasone represents a favorable option for patients with multiple myeloma and any cytogenetic profile, based on comparable objective responses rates and progression-free survival results from 2 clinical trials.

Efficacy of Pertuzumab/Trastuzumab Deruxtecan Combo Under Investigation in DESTINY-Breast09 for HER2+ Breast Cancer

December 9th 2021

Prior research has shown that the combination of trastuzumab deruxtecan plus pertuzumab may be superior to T-trastuzumab deruxtecan alone in patients with HER2-positive metastatic breast cancer and the combination is now under examination in the phase 3 DESTINY-Breast09 trial.

Switch to Darolutamide Maintenance Improves Survival in Taxane and NHA Pretreated mCRPC

September 19th 2021

Switching maintenance to darolutamide following taxane-based therapy with at least 1 novel hormonal agent showed statistically significant but clinically modest improvement in radiographic progression-free survival and event-free survival in patents with metastatic castration-resistant prostate cancer.